United States - English - NLM (National Library of Medicine)

directrx - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide 50 mg - zonisamide is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide is contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.

Malta - English - Medicines Authority

doc generici srl via turati, 40-20121, milano, italy - zonisamide - hard capsule - zonisamide 25 mg - antiepileptics

Malta - English - Medicines Authority

doc generici srl via turati, 40-20121, milano, italy - zonisamide - hard capsule - zonisamide 50 mg - antiepileptics

Malta - English - Medicines Authority

doc generici srl via turati, 40-20121, milano, italy - zonisamide - hard capsule - zonisamide 100 mg - antiepileptics

Malta - English - Medicines Authority

endo ventures limited first floor, minerva house, simmonscourt road, ballsbridge, dublin 4, ireland - zonisamide - hard capsule - zonisamide 25 mg - antiepileptics

Malta - English - Medicines Authority

endo ventures limited first floor, minerva house, simmonscourt road, ballsbridge, dublin 4, ireland - zonisamide - hard capsule - zonisamide 50 mg - antiepileptics

Malta - English - Medicines Authority

endo ventures limited first floor, minerva house, simmonscourt road, ballsbridge, dublin 4, ireland - zonisamide - hard capsule - zonisamide 100 mg - antiepileptics

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide capsules are contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide capsules has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.

United States - English - NLM (National Library of Medicine)

direct rx - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide capsules usp are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide capsules usp are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide capsules are contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. zonisamide capsules are contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal ... the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats expo

United States - English - NLM (National Library of Medicine)

proficient rx lp - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide capsules usp are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide capsules are contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.